IRB #

STUDY00015572

Title

An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Principal Investigator

Matthew Taylor

Study Purpose

The purpose of this study is to evaluate the effectiveness and safety of lenvatinib in patients who have anaplastic thyroid cancer.

Medical Condition(s)

Thyroid cancer

Eligibility Criteria

1. Confirmed diagnosis of anaplastic thyroid cancer (ATC).
2. Must have adequately controlled blood pressure (less than or equal to 140/90).
3. Must have sufficient performance status and bone marrow function.

Other criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Treatment will last approximately 6 months or longer. If you are still receiving study treatment at the time the study ends, you may continue taking commercially available lenvatinib. Also, until the study ends, you or your family will be contacted by telephone or e-mail about every 3 months after your last dose of study drug to find out how you are doing overall, whether your cancer has worsened, and what anticancer medications you may be taking.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Eisai, Inc.

Recruitment End

12/31/2030

Compensation Provided

No


Go Back